MADRIGAL PHARMACEUTICALS, INC. 8-K

What Happened
Madrigal Pharmaceuticals, Inc. (MDGL) announced it entered into a First Amendment to its December 18, 2008 Research, Development, and Commercialization Agreement with F. Hoffmann‑La Roche Ltd and Hoffmann‑La Roche Inc., effective January 29, 2026. Under the amendment, Madrigal will have the full and exclusive right and discretion to control all patent term adjustments and patent term extensions applicable to Rezdiffra, including patents owned solely by Roche and patents jointly owned by the parties. The amendment also states that royalties payable to Roche based on net sales of Rezdiffra will not be reduced until the expiration of certain patent term extensions that have been, or could have been, filed.

Key Details

• Effective date of amendment: January 29, 2026; 8-K filed January 30, 2026.
• Parties: Madrigal Pharmaceuticals and Roche (F. Hoffmann‑La Roche Ltd and Hoffmann‑La Roche Inc.).
• Rights granted: Madrigal obtains exclusive control over patent term adjustments and extensions for Rezdiffra (including Roche-owned and jointly owned patents).
• Royalty impact: Royalties to Roche will remain in place and will not be reduced until specified patent term extensions expire.
• The amendment is filed as Exhibit 10.1 to the 8‑K (certain portions redacted per Regulation S‑K).

Why It Matters
Granting Madrigal exclusive control over patent term adjustments and extensions for Rezdiffra affects who decides on actions that can extend patent life and commercial exclusivity for the drug. For investors, that control can influence how long Madrigal may market Rezdiffra without generic competition and thus can affect future sales and revenue timing. The amendment also preserves Roche’s royalty payments until certain extensions expire, which is a material payment-term detail to monitor when assessing future net revenue from Rezdiffra.